FemPulse Appoints Dr. Robert Kieval as Chief Scientific and Clinical Officer

MINNEAPOLIS, March 05, 2019 (GLOBE NEWSWIRE) -- FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of overactive bladder (OAB) in women, is pleased to share the appointment of Dr. Robert Kieval as Chief Scientific and Clinical Officer. Dr. Kieval is a medical technology industry veteran, with over 25 years of experience in innovating, financing, and commercializing novel technologies. Dr. Kieval is responsible for continuing to expand the Company’s significant clinical and scientific evidence portfolio.

“We are excited to have Rob join the FemPulse team as his extensive knowledge and recognition within the healthcare industry will provide invaluable guidance as we diligently work to develop an effective, accessible and affordable solution to treat OAB,” commented Donald Deyo, President and Chief Executive Officer of FemPulse. “Rob has the direct experience and qualifications to help us navigate FemPulse to even greater success.”

Dr. Kieval added, “I am honored to join such a dedicated team focused on improving patient standard of care and quality of life as we develop a truly unique solution for a large unmet need. I look forward to helping bring this needed product to market that has the potential to significantly benefit the nearly 1 in 6 women who suffer from OAB.”

Dr. Kieval has over 15 years of C-level leadership experience and a track record of success in innovating, financing and commercializing sophisticated medical technology. His previous roles include Founder and CEO at CVRx, Inc., Business Development Director at ProtoStar, Inc., a medical technology incubator backed by several prominent venture capital firms, and divisional Medical Director at Medtronic, Inc. As CEO of CVRx, Dr. Kieval raised $60M in capital to support the company.  The company’s flagship product, an implantable neuromodulation device, is market-approved in Europe for treating heart failure and hypertension, and is in a Phase III clinical trial in the United States.  Dr. Kieval has been a strong industry advocate. He currently serves on the board of The Medical Alley Association, where he is a past Chairman, previously served for 10 years on the board of The Medical Device Manufacturers Association, and has testified before Congress on behalf of the medical technology industry.  In 2006, Dr. Kieval was named an Innovator of the Year by Twin Cities Finance & Commerce. Subsequently, in 2012, Twin Cities Business listed him as one of Minnesota’s top inventors. He is a named inventor on over 70 patents and has contributed to numerous scientific publications. Dr. Kieval holds doctorate degrees in Veterinary Medicine and in Physiology from The University of Pennsylvania.

About FemPulse Corporation
FemPulse Corporation is a privately held clinical-stage bioelectronic medicine company focused on treating women with overactive bladder. The Company is developing the FemPulse System, an elegant neuromodulation platform, intended to provide mild electrical nerve stimulation to regulate bladder function and relieve the symptoms of OAB. The small, vaginal ring is disposable and may remain indwelling for days or weeks, affording discreet, personalized, continuous and self-managed therapy. For more information, visit www.fempulse.com.

Investor Relations Contact:
Lee Roth / Emma Poalillo
The Ruth Group
646-536-7012 / 7024
lroth@theruthgroup.com / epoalillo@theruthgroup.com

Media Contact:
Kirsten Thomas
The Ruth Group